/PRNewswire/ -- Mallinckrodt plc and Endo, Inc. today announced that they have completed their merger to create a global, scaled, diversified therapeutics. Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates. About Us Solving complex challenges with a diverse product portfolio Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products. Listening for Needs, Delivering Solutions | Mallinckrodt Pharmaceuticals combined with Endo in 2025 to better serve customers and improve outcomes for the patients we support. This site is an online medical resource intended to provide scientifically accurate, evidence-based, and balanced medical information on Mallinckrodt products. The merger and corporate makeover represent a fresh start for Mallinckrodt and Endo, which have both faced significant financial pressure in recent years over their alleged roles in the opioid. Mallinckrodt. Mallinckrodt Pharmaceuticals plc is an Irish-American manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. [2] In 2017, it had 5,500 employees and sales of $3.2 billion, of which $2.9 billion was from the U.S. healthcare system. [3].